Specialty drug spend increased by 15 percent to $121 billion in 2015 and is projected to rise even more. Budget-conscious payers need to implement novel management strategies that anticipate the cost of specialty medications before they’re available. A summary of efficacy data for high-impact specialty pipeline drugs expected to reach the market, including their place in therapy and budgetary impact. Also featured are strategies to mitigate costs of these cutting-edge medications and compare them to current therapy options.
Planning for the 2017 Specialty Drug Spend: When Costs are Steep but Pockets are Not Deep
Wednesday, November 16, 2016
Eastern Medicaid Pharmacy Administrators Association 40th Annual Meeting